Given the favorable data for the FAST and FAST Forward trials, can we consider those ultra-hypofractionated whole breast radiation schemes to be standard of care for early stage breast cancer?  

With respect to FAST (28.5 Gy in 5 fx in 5 weeks), can be considered based on 10-year data (https://www.astro.org/ASTRO/media/ASTRO/Meetings%20and%20Education/PDFs/AM18/LBA18.pdf). Local control rates were low in all arms but in general, I limit this to patients who can't do standard hypofractionate...

While there is only 5-year data, I am starting to use FAST-Forward in selected patients with significant transportation or COVID issues, and in whom I don't expect challenges achieving dose homogeneity with a 3D treatment plan. In the first few we've treated - I have followed weekly after treatment ...